Fierce Pharma August 21, 2024
A survey of more than 800 biopharma executives shows that sustainability has become an increasingly important priority but that companies are struggling to achieve it and as a result are putting their business at risk.
The study—which was conducted by Cytiva and Financial Times research unit FT Longitude—tabulated the input of execs from firms in 18 different countries. Of the respondents, 26% hold C-suite roles and 30% represent companies that generate more than $1 billion in annual revenue.
“We want to drive a conversation around innovation and strategy on sustainability,” Emmanuel Abate, Cytiva’s sustainability and corporate responsibility chief, said in a release. “These findings highlight where we as an industry must collaborate and push for better progress and prove the...
Today's Sponsors
Today's Sponsor